Business
Directorate Change
Directorate Change.
About this update from Immupharma Plc
[{"type":"text","content":"\n\n \n11 August 2023\nImmuPharma PLC\n(\"ImmuPharma\" or the \"Company\")\nBOARD STRENGTHENED AHEAD OF NEXT PHASE OF COMPANY PROGRESSION\nImmuPharma PLC (LSE:IMM), the specialist drug discovery and development company, provides notification of changes to its Board of Directors.\nIt has been a pivotal 2023 for ImmuPharma, specifically within its P140 autoimmune platform.\nMost recently in June, the Company announced that, after receiving comprehensive guidance from the Food & Drug Administration (\"FDA\") on the new Phase 2/3 adaptive clinical trial protocol for the lead programme for the treatment of patients with systemic lupus erythematosus (\"SLE/Lupus\"), it is moving forward with the study, together with its US partner Avion.\nPositive progress on the P140 platform was also announced in May for a second high medical need disease, chronic idiopathic demyelinating polyneuropathy (\"CIDP\"). The Company received positive feedback from the FDA at a pre-IND meeting for a late-stage Phase 2/3 adaptive clinical program in patients, which is a further debilitating auto-immune condition within the Company's P140 platform.\nIn parallel with advancements in the late-stage clinical developments, the Company is also actively in discussions with a number of potential licensing partners for programmes across the Company's development portfolio.\nIn order to align with the new phase of progress, the Company recognised the need to add further skills and experience to the Board to ensure that we have the requisite Board composition for the next stage of evolution of the business. \nWe are therefore delighted to announce today the appointment of Dr Laurence Reilly as Senior independent Non-Executive Director and Chair of the Audit Committee. Dr Reilly brings extensive experience in managing late-stage clinical programs through to approval, in addition to commercial and business development experience.\n \nHe is currently Vice President of Research & Investments, working with Royalty Pharma, a New York based life science investment company focussing on acquisition of biopharmaceutical royalties and funding of innovation across the biopharmaceutical industry.\n \nThrough his consulting practice (Acumen Life Science Investment Consulting) Dr Reilly has provided strategic consulting and due-diligence services to...